Copyright
©The Author(s) 2024.
World J Clin Oncol. Dec 24, 2024; 15(12): 1520-1527
Published online Dec 24, 2024. doi: 10.5306/wjco.v15.i12.1520
Published online Dec 24, 2024. doi: 10.5306/wjco.v15.i12.1520
Name | Target | Stage | Potential pros | Potential cons |
PROTACs | ||||
JB170 | AURKA | Preclinical | Versatile drug design potential; high target specificity; reduced risk of drug resistance | Higher complexity in design and development cost off-target effects; limited clinical data available |
BETd-260 | BET | Preclinical | ||
ARV-771 | BRD2/3/4 | Preclinical | ||
CP-10 | CDK6 | Preclinical | ||
BSJ-03-123 | CDK6 | Preclinical | ||
ADCs | ||||
MGC018 | CD276 | Preclinical | High target specificity; reduced systemic toxicity | Limited scope of targetable antigens off-target effects; challenges in stability and drug release |
ABBV-400 | MET | Preclinical | ||
hYP7-DC | GPC3 | Preclinical | ||
CLDN6-DM1 | CLDN6 | Preclinical | ||
mRNA vaccines | ||||
PGV002 | Neoantigen | Phase I | Personalized treatment; potential; potential for broader; immune response; lower drug toxic | Potential for immune-related; side effects; Limited clinical data in; cancer treatment |
PCV | Neoantigen | Phase I | ||
ABOR2014 | Neoantigen | Phase I |
- Citation: Du H, Chen HB, Zhao Y. Exploring a new chapter in traditional Chinese medicine: The potential of Calculus bovis in liver cancer treatment. World J Clin Oncol 2024; 15(12): 1520-1527
- URL: https://www.wjgnet.com/2218-4333/full/v15/i12/1520.htm
- DOI: https://dx.doi.org/10.5306/wjco.v15.i12.1520